Genetics and epigenetics of adrenocortical tumors

Molecular and Cellular Endocrinology

Volumn 386, Issue 1-2, 2014, Pages 67-84

  Lerario, Antonio M ^a   Moraitis, Andreas ^b   Hammer, Gary D ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adenoma; Adrenocortical; Carcinoma; Epigenetics; Genetics; Hyperplasia

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROCORTISONE; MICRORNA; MINERALOCORTICOID; PROTEIN P53; VASCULOTROPIN;

ADENOMA; ADRENAL CORTEX TUMOR; ALBRIGHT SYNDROME; BECKWITH WIEDEMANN SYNDROME; CARCINOGENESIS; CHROMOSOME DISORDER; DNA METHYLATION; EPIGENETICS; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GARDNER SYNDROME; GENE; GENETIC DISORDER; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MOLECULAR PATHOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PKA; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TP53 GENE; WNT SIGNALING PATHWAY;

ADENOMA; ADRENOCORTICAL; CARCINOMA; EPIGENETICS; GENETICS; HYPERPLASIA;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ANIMALS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; HUMANS; SIGNAL TRANSDUCTION;

EID: 84896720825     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.10.028     Document Type: Review

References (191)

1. Adam P., Hahner S., Hartmann M., Heinrich B., Quinkler M., Willenberg H.S., Saeger W., Sbiera S., Schmull S., Voelker H.U., Strobel P., Allolio B., Fassnacht M. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod. Pathol. 2010, 23(12):1596-1604.
2. Affara N.I., Robertson F.M. Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis. In Vivo 2004, 18(5):525-542.
3. Almeida M.Q., Fragoso M.C., Lotfi C.F., Santos M.G., Nishi M.Y., Costa M.H., Lerario A.M., Maciel C.C., Mattos G.E., Jorge A.A., Mendonca B.B., Latronico A.C. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93(9):3524-3531.
4. Almeida M.Q., Muchow M., Boikos S., Bauer A.J., Griffin K.J., Tsang K.M., Cheadle C., Watkins T., Wen F., Starost M.F., Bossis I., Nesterova M., Stratakis C.A. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum. Mol. Genet. 2010, 19(8):1387-1398.
5. Almeida M.Q., Soares I.C., Ribeiro T.C., Fragoso M.C., Marins L.V., Wakamatsu A., Ressio R.A., Nishi M.Y., Jorge A.A., Lerario A.M., Alves V.A., Mendonca B.B., Latronico A.C. Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J. Clin. Endocrinol. Metab. 2010, 95(3):1458-1462.
6. Almeida M.Q., Harran M., Bimpaki E.I., Hsiao H.P., Horvath A., Cheadle C., Watkins T., Nesterova M., Stratakis C.A. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J. Clin. Endocrinol. Metab. 2011, 96(4):E728-E738.
7. Anselmo J., Medeiros S., Carneiro V., Greene E., Levy I., Nesterova M., Lyssikatos C., Horvath A., Carney J.A., Stratakis C.A. A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer. J. Clin. Endocrinol. Metab. 2012, 97(2):351-359.
8. Arnaldi G., Boscaro M. Adrenal incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26(4):405-419.
9. Azizan E.A., Murthy M., Stowasser M., Gordon R., Kowalski B., Xu S., Brown M.J., O'Shaughnessy K.M. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012, 59(3):587-591.
10. Bachinski L.L., Olufemi S.E., Zhou X., Wu C.C., Yip L., Shete S., Lozano G., Amos C.I., Strong L.C., Krahe R. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Canc. Res. 2005, 65(2):427-431.
11. Bagri A., Kouros-Mehr H., Leong K.G., Plowman G.D. Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends Mol. Med. 2010, 16(3):122-132.
12. Bakhoum S.F., Compton D.A. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J. Clin. Invest. 2012, 122(4):1138-1143.
13. Barlaskar F.M., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G., Giordano T.J., Ben-Josef E., Hammer G.D. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2009, 94(1):204-212.
14. Barreau O., Assie G., Wilmot-Roussel H., Ragazzon B., Baudry C., Perlemoine K., Rene-Corail F., Bertagna X., Dousset B., Hamzaoui N., Tissier F., de Reynies A., Bertherat J. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J. Clin. Endocrinol. Metab. 2013, 98(1):E174-E184.
15. Barzon L., Chilosi M., Fallo F., Martignoni G., Montagna L., Palu G., Boscaro M. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur. J. Endocrinol. 2001, 145(2):207-212.
16. Bernard M.H., Sidhu S., Berger N., Peix J.L., Marsh D.J., Robinson B.G., Gaston V., Le Bouc Y., Gicquel C. A case report in favor of a multistep adrenocortical tumorigenesis. J. Clin. Endocrinol. Metab. 2003, 88(3):998-1001.
17. Bertherat J., Groussin L., Sandrini F., Matyakhina L., Bei T., Stergiopoulos S., Papageorgiou T., Bourdeau I., Kirschner L.S., Vincent-Dejean C., Perlemoine K., Gicquel C., Bertagna X., Stratakis C.A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Canc. Res. 2003, 63(17):5308-5319.
18. Bertherat J., Horvath A., Groussin L., Grabar S., Boikos S., Cazabat L., Libe R., Rene-Corail F., Stergiopoulos S., Bourdeau I., Bei T., Clauser E., Calender A., Kirschner L.S., Bertagna X., Carney J.A., Stratakis C.A. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 2009, 94(6):2085-2091.
19. Beuschlein F. Regulation of aldosterone secretion: from physiology to disease. Eur. J. Endocrinol. 2013, 168(6):R85-R93.
20. Beuschlein F., Reincke M., Karl M., Travis W.D., Jaursch-Hancke C., Abdelhamid S., Chrousos G.P., Allolio B. Clonal composition of human adrenocortical neoplasms. Canc. Res. 1994, 54(18):4927-4932.
21. Bimpaki E.I., Nesterova M., Stratakis C.A. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur. J. Endocrinol. 2009, 161(1):153-161.
22. Bos J.L. Ras oncogenes in human cancer: a review. Canc. Res. 1989, 49(17):4682-4689.
23. Bougeard G., Sesboue R., Baert-Desurmont S., Vasseur S., Martin C., Tinat J., Brugieres L., Chompret A., de Paillerets B.B., Stoppa-Lyonnet D., Bonaiti-Pellie C., Frebourg T., French L.F.S.w.g. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J. Med. Genet. 2008, 45(8):535-538.
24. Bourdeau I., Matyakhina L., Stergiopoulos S.G., Sandrini F., Boikos S., Stratakis C.A. 17q22-24 chromosomal losses and alterations of protein kinase a subunit expression and activity in adrenocorticotropin-independent macronodular adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2006, 91(9):3626-3632.
25. Bovio S., Cataldi A., Reimondo G., Sperone P., Novello S., Berruti A., Borasio P., Fava C., Dogliotti L., Scagliotti G.V., Angeli A., Terzolo M. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 2006, 29(4):298-302.
26. Bowlby L.S., DeBault L.E., Abraham S.R. Flow cytometric analysis of adrenal cortical tumor DNA. Relationship between cellular DNA and histopathologic classification. Cancer 1986, 58(7):1499-1505.
27. Brown R.J., Kelly M.H., Collins M.T. Cushing syndrome in the McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 2010, 95(4):1508-1515.
28. Carney J.A., Gordon H., Carpenter P.C., Shenoy B.V., Go V.L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985, 64(4):270-283.
29. Carss K.J., Stowasser M., Gordon R.D., O'Shaughnessy K.M. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J. Hum. Hypertens. 2011, 25(9):560-564.
30. Chabre O., Libe R., Assie G., Barreau O., Bertherat J., Bertagna X., Feige J.J., Cherradi N. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr. Relat. Can. 2013, 20(4):579-594.
31. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., Debelenko L.V., Zhuang Z., Lubensky I.A., Liotta L.A., Crabtree J.S., Wang Y., Roe B.A., Weisemann J., Boguski M.S., Agarwal S.K., Kester M.B., Kim Y.S., Heppner C., Dong Q., Spiegel A.M., Burns A.L., Marx S.J. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276(5311):404-407.
32. Chapman A., Durand J., Ouadi L., Bourdeau I. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors. J. Clin. Endocrinol. Metab. 2011, 96(9):E1477-E1481.
33. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331(6018):768-772.
34. Chompret A., Brugieres L., Ronsin M., Gardes M., Dessarps-Freichey F., Abel A., Hua D., Ligot L., Dondon M.G., Bressac-de Paillerets B., Frebourg T., Lemerle J., Bonaiti-Pellie C., Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Can. 2000, 82(12):1932-1937.
35. Chompret A., Abel A., Stoppa-Lyonnet D., Brugieres L., Pages S., Feunteun J., Bonaiti-Pellie C. Sensitivity and predictive value of criteria for p53 germline mutation screening. J. Med. Genet. 2001, 38(1):43-47.
36. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102(39):13944-13949.
37. Custodio G., Taques G.R., Figueiredo B.C., Gugelmin E.S., Oliveira Figueiredo M.M., Watanabe F., Pontarolo R., Lalli E., Torres L.F. Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One 2011, 6(3):e18015.
38. Custódio G., Komechen H., Figueiredo F.R., Fachin N.D., Pianovski M.A., Figueiredo B.C. Molecular epidemiology of adrenocortical tumors in southern Brazil. Mol. Cell. Endocrinol. 2012, 351(1):44-51.
39. Czech B., Hannon G.J. Small RNA sorting: matchmaking for Argonautes. Nat. Rev. Genet. 2011, 12(1):19-31.
40. Dall'Asta C., Ballare E., Mantovani G., Ambrosi B., Spada A., Barbetta L., Colombo P., Travaglini P., Loli P., Beck-Peccoz P. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm. Metab. Res. 2004, 36(8):578-583.
41. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22(22):4632-4642.
42. de Fraipont F., El Atifi M., Gicquel C., Bertagna X., Chambaz E.M., Feige J.J. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. J. Clin. Endocrinol. Metab. 2000, 85(12):4734-4741.
43. de Fraipont F., El Atifi M., Cherradi N., Le Moigne G., Defaye G., Houlgatte R., Bertherat J., Bertagna X., Plouin P.F., Baudin E., Berger F., Gicquel C., Chabre O., Feige J.J. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005, 90(3):1819-1829.
44. de Joussineau C., Sahut-Barnola I., Levy I., Saloustros E., Val P., Stratakis C.A., Martinez A. The cAMP pathway and the control of adrenocortical development and growth. Mol. Cell. Endocrinol. 2012, 351(1):28-36.
45. De Martino M.C., van Koetsveld P.M., Pivonello R., Hofland L.J. Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 2010, 92(Suppl 1):28-34.
46. De Martino M.C., van Koetsveld P.M., Feelders R.A., Sprij-Mooij D., Waaijers M., Lamberts S.W., de Herder W.W., Colao A., Pivonello R., Hofland L.J. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. Endocr. Relat. Can. 2012, 19(3):351-364.
47. de Reynies A., Assie G., Rickman D.S., Tissier F., Groussin L., Rene-Corail F., Dousset B., Bertagna X., Clauser E., Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27(7):1108-1115.
48. DiGiammarino E.L., Lee A.S., Cadwell C., Zhang W., Bothner B., Ribeiro R.C., Zambetti G., Kriwacki R.W. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat. Struct. Biol. 2002, 9(1):12-16.
49. Doghman M., Lalli E. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Mol. Cell. Endocrinol. 2012, 364(1-2):101-104.
50. Doghman M., Karpova T., Rodrigues G.A., Arhatte M., De Moura J., Cavalli L.R., Virolle V., Barbry P., Zambetti G.P., Figueiredo B.C., Heckert L.L., Lalli E. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 2007, 21(12):2968-2987.
51. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta-Del Valle M.H., Figueiredo B.C., Zambetti G.P., Lalli E. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Canc. Res. 2010, 70(11):4666-4675.
52. Drelon C., Berthon A., Ragazzon B., Tissier F., Bandiera R., Sahut-Barnola I., de Joussineau C., Batisse-Lignier M., Lefrancois-Martinez A.M., Bertherat J., Martinez A., Val P. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One 2012, 7(8):e44171.
53. Edgren M., Eriksson B., Wilander E., Westlin J.E., Nilsson S., Oberg K. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Antican. Res. 1997, 17(2B):1303-1309.
54. Else T., Giordano T.J., Hammer G.D. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2008, 93(4):1442-1449.
55. Fassnacht M., Allolio B. Clinical management of adrenocortical carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23(2):273-289.
56. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev. Mol. Diagn. 2010, 10(3):297-308.
57. Figueiredo B.C., Stratakis C.A., Sandrini R., DeLacerda L., Pianovsky M.A., Giatzakis C., Young H.M., Haddad B.R. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J. Clin. Endocrinol. Metab. 1999, 84(3):1116-1121.
58. Figueiredo B.C., Ribeiro R.C., Zambetti G., Haddad B., Pianovsky M.D., Pereira R.M., DeLacerda L., Sandrini R. Amplification of 9q34 in childhood adrenocortical tumors: a specific feature unrelated to ethnic origin or living conditions. Braz. J. Med. Biol. Res. 2000, 33(10):1217-1224.
59. Fonseca A.L., Kugelberg J., Starker L.F., Scholl U., Choi M., Hellman P., Akerström G., Westin G., Lifton R.P., Björklund P., Carling T. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Can. 2012, 51(10):949-960.
60. Fraenkel M., Gueorguiev M., Barak D., Salmon A., Grossman A.B., Gross D.J. Everolimus therapy for progressive adrenocortical cancer. Endocrine 2012, 51(10):949-960.
61. Fragoso M.C., Domenice S., Latronico A.C., Martin R.M., Pereira M.A., Zerbini M.C., Lucon A.M., Mendonca B.B. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J. Clin. Endocrinol. Metab. 2003, 88(5):2147-2151.
62. Fragoso M.C., Almeida M.Q., Mazzuco T.L., Mariani B.M., Brito L.P., Goncalves T.C., Alencar G.A., Lima Lde O., Faria A.M., Bourdeau I., Lucon A.M., Freire D.S., Latronico A.C., Mendonca B.B., Lacroix A., Lerario A.M. Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur. J. Endocrinol. 2012, 166(1):61-67.
63. Gallo-Payet N., Payet M.D. Mechanism of action of ACTH: beyond cAMP. Microsc. Res. Tech. 2003, 61(3):275-287.
64. Gao Z.H., Suppola S., Liu J., Heikkila P., Janne J., Voutilainen R. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. J. Clin. Endocrinol. Metab. 2002, 87(3):1170-1176.
65. Garritano S., Gemignani F., Palmero E.I., Olivier M., Martel-Planche G., Le Calvez-Kelm F., Brugieres L., Vargas F.R., Brentani R.R., Ashton-Prolla P., Landi S., Tavtigian S.V., Hainaut P., Achatz M.I. Detailed haplotype analysis at the TP53 locus in p. R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum. Mutat. 2010, 31(2):143-150.
66. Gaujoux S., Tissier F., Groussin L., Libe R., Ragazzon B., Launay P., Audebourg A., Dousset B., Bertagna X., Bertherat J. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93(10):4135-4140.
67. Gaujoux S., Pinson S., Gimenez-Roqueplo A.P., Amar L., Ragazzon B., Launay P., Meatchi T., Libe R., Bertagna X., Audebourg A., Zucman-Rossi J., Tissier F., Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin. Can. Res. 2010, 16(21):5133-5141.
68. Gibril F., Schumann M., Pace A., Jensen R.T. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004, 83(1):43-83.
69. Gicquel C., Leblond-Francillard M., Bertagna X., Louvel A., Chapuis Y., Luton J.P., Girard F., Le Bouc Y. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin. Endocrinol. (Oxf.) 1994, 40(4):465-477.
70. Gicquel C., Raffin-Sanson M.L., Gaston V., Bertagna X., Plouin P.F., Schlumberger M., Louvel A., Luton J.P., Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 1997, 82(8):2559-2565.
71. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J.M., Schlumberger M., Plouin P.F., Luton J.P., Le Bouc Y. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Can. Res. 2001, 61(18):6762-6767.
72. Giordano T.J., Thomas D.G., Kuick R., Lizyness M., Misek D.E., Smith A.L., Sanders D., Aljundi R.T., Gauger P.G., Thompson N.W., Taylor J.M., Hanash S.M. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003, 162(2):521-531.
73. Giordano T.J., Kuick R., Else T., Gauger P.G., Vinco M., Bauersfeld J., Sanders D., Thomas D.G., Doherty G., Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Can. Res. 2009, 15(2):668-676.
74. Griniatsos J.E., Dimitriou N., Zilos A., Sakellariou S., Evangelou K., Kamakari S., Korkolopoulou P., Kaltsas G. Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gene. World J. Surg. Oncol. 2011, 9:6.
75. Grumbach M.M., Biller B.M., Braunstein G.D., Campbell K.K., Carney J.A., Godley P.A., Harris E.L., Lee J.K., Oertel Y.C., Posner M.C., Schlechte J.A., Wieand H.S. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann. Int. Med. 2003, 138(5):424-429.
76. Guimier A., Ragazzon B., Assie G., Tissier F., Dousset B., Bertherat J., Gaujoux S. AXIN genetic analysis in adrenocortical carcinomas updated. J. Endocrinol. Invest. 2013.
77. Half E., Bercovich D., Rozen P. Familial adenomatous polyposis. Orphanet J. Rare Dis. 2009, 4:22.
78. Haluska P., Worden F., Olmos D., Yin D., Schteingart D., Batzel G.N., Paccagnella M.L., de Bono J.S., Gualberto A., Hammer G.D. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Can. Chemother. Pharmacol. 2010, 65(4):765-773.
79. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
80. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
81. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18(16):1926-1945.
82. Heaton J.H., Wood M.A., Kim A.C., Lima L.O., Barlaskar F.M., Almeida M.Q., Fragoso M.C., Kuick R., Lerario A.M., Simon D.P., Soares I.C., Starnes E., Thomas D.G., Latronico A.C., Giordano T.J., Hammer G.D. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am. J. Pathol. 2012, 181(3):1017-1033.
83. Hermsen I.G., Haak H.R., de Krijger R.R., Kerkhofs T.M., Feelders R.A., de Herder W.W., Wilmink H., Smit J.W., Gelderblom H., Miranda N.F., van Eijk R., Wezel T.V., Morreau H. Mutational analyses of EGFR and downstream pathways in adrenocortical carcinoma. Eur. J. Endocrinol 2013, 169(1):51-58.
84. Herrmann L.J., Heinze B., Fassnacht M., Willenberg H.S., Quinkler M., Reisch N., Zink M., Allolio B., Hahner S. TP53 germline mutations in adult patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2012, 97(3):E476-E485.
85. Hisada M., Garber J.E., Fung C.Y., Fraumeni J.F., Li F.P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Nat. Can. Inst. 1998, 90(8):606-611.
86. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. P53 mutations in human cancers. Science 1991, 253(5015):49-53.
87. Horvath A., Mathyakina L., Vong Q., Baxendale V., Pang A.L., Chan W.Y., Stratakis C.A. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. J. Clin. Endocrinol. Metab. 2006, 91(2):584-596.
88. Hsiao H.P., Kirschner L.S., Bourdeau I., Keil M.F., Boikos S.A., Verma S., Robinson-White A.J., Nesterova M., Lacroix A., Stratakis C.A. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J. Clin. Endocrinol. Metab. 2009, 94(8):2930-2937.
89. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27(34):5848-5856.
90. Jackson R.V., Lafferty A., Torpy D.J., Stratakis C. New genetic insights in familial hyperaldosteronism. Ann. NY Acad. Sci. 2002, 970:77-88.
91. James L.A., Kelsey A.M., Birch J.M., Varley J.M. Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br. J. Can. 1999, 81(2):300-304.
92. Kamio T., Shigematsu K., Sou H., Kawai K., Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum. Pathol. 1990, 21(3):277-282.
93. Karamurzin Y., Zeng Z., Stadler Z.K., Zhang L., Ouansafi I., Al-Ahmadie H.A., Sempoux C., Saltz L.B., Soslow R.A., O'Reilly E.M., Paty P.B., Coit D.G., Shia J., Klimstra D.S. Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. Hum. Pathol. 2012, 43(10):1677-1687.
94. Karim R., Tse G., Putti T., Scolyer R., Lee S. The significance of the Wnt pathway in the pathology of human cancers. Pathology 2004, 36(2):120-128.
95. Kartheuser A., Walon C., West S., Breukel C., Detry R., Gribomont A.C., Hamzehloei T., Hoang P., Maiter D., Pringot J., Rahier J., Khan P.M., Curtis A., Burn J., Fodde R., Verellen-Dumoulin C. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3' APC mutation. J. Med. Genet. 1999, 36(1):65-67.
96. Kim W., Kim M., Jho E.H. Wnt/beta-catenin signalling: from plasma membrane to nucleus. Biochem. J. 2013, 450(1):9-21.
97. Kirschner L.S., Carney J.A., Pack S.D., Taymans S.E., Giatzakis C., Cho Y.S., Cho-Chung Y.S., Stratakis C.A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat. Genet. 2000, 26(1):89-92.
98. Kjellman M., Kallioniemi O.P., Karhu R., Hoog A., Farnebo L.O., Auer G., Larsson C., Backdahl M. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Can. Res. 1996, 56(18):4219-4223.
99. Kjellman M., Roshani L., Teh B.T., Kallioniemi O.P., Hoog A., Gray S., Farnebo L.O., Holst M., Backdahl M., Larsson C. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab. 1999, 84(2):730-735.
100. Klein F.A., Kay S., Ratliff J.E., White F.K., Newsome H.H. Flow cytometric determinations of ploidy and proliferation patterns of adrenal neoplasms: an adjunct to histological classification. J. Urol. 1985, 134(5):862-866.
101. Kolomecki K., Stepien H., Bartos M., Kuzdak K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocrin. Regul. 2001, 35(1):9-16.
102. Kotoula V., Sozopoulos E., Litsiou H., Fanourakis G., Koletsa T., Voutsinas G., Tseleni-Balafouta S., Mitsiades C.S., Wellmann A., Mitsiades N. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr. Relat. Can. 2009, 16(2):565-572.
103. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23(2):245-259.
104. Lam W.W., Hatada I., Ohishi S., Mukai T., Joyce J.A., Cole T.R., Donnai D., Reik W., Schofield P.N., Maher E.R. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J. Med. Genet. 1999, 36(7):518-523.
105. Lapunzina P. Risk of tumorigenesis in overgrowth syndromes: a comprehensive review. Am. J. Med. Genet. C Semin. Med. Genet. 2005, 137C(1):53-71.
106. Latronico A.C., Reincke M., Mendonca B.B., Arai K., Mora P., Allolio B., Wajchenberg B.L., Chrousos G.P., Tsigos C. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J. Clin. Endocrinol. Metab. 1995, 80(3):875-877.
107. Latronico A.C., Pinto E.M., Domenice S., Fragoso M.C., Martin R.M., Zerbini M.C., Lucon A.M., Mendonca B.B. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001, 86(10):4970-4973.
108. Lee P.A., Van Dop C., Migeon C.J. McCune-Albright syndrome. Long-term follow-up. JAMA 1986, 256(21):2980-2984.
109. Leighton P.A., Saam J.R., Ingram R.S., Stewart C.L., Tilghman S.M. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev. 1995, 9(17):2079-2089.
110. Li F.P., Fraumeni J.F., Mulvihill J.J., Blattner W.A., Dreyfus M.G., Tucker M.A., Miller R.W. A cancer family syndrome in twenty-four kindreds. Can. Res. 1988, 48(18):5358-5362.
111. Libe R., Groussin L., Tissier F., Elie C., Rene-Corail F., Fratticci A., Jullian E., Beck-Peccoz P., Bertagna X., Gicquel C., Bertherat J. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Can. Res. 2007, 13(3):844-850.
112. Light K., Jenkins P.J., Weber A., Perrett C., Grossman A., Pistorello M., Asa S.L., Clayton R.N., Clark A.J. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?. Life Sci. 1995, 56(18):1523-1527.
113. Limon J., Dal Cin P., Kakati S., Huben R.P., Sandberg A.A. Cytogenetic findings in a primary adrenocortical carcinoma. Can. Genet. Cytogenet. 1987, 26(2):271-277.
114. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8(8):627-644.
115. Loeb L.A. A mutator phenotype in cancer. Can. Res. 2001, 61(8):3230-3239.
116. Logie A., Boulle N., Gaston V., Perin L., Boudou P., Le Bouc Y., Gicquel C. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol. 1999, 23(1):23-32.
117. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482(7385):347-355.
118. Luo X., Ikeda Y., Parker K.L. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994, 77(4):481-490.
119. Mariniello B., Rosato A., Zuccolotto G., Rubin B., Cicala M.V., Finco I., Iacobone M., Frigo A.C., Fassina A., Pezzani R., Mantero F. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocrinol. Relat. Can. 2012, 19(4):527-539.
120. Marks J.L., Wyandt H.E., Beazley R.M., Milunsky J.M., Sheahan K., Milunsky A. Cytogenetic studies of an adrenal cortical carcinoma. Can. Genet. Cytogenet. 1992, 61(1):96-98.
121. Marshall W.H., Martin F.I., Mackay I.R. Gardner's syndrome with adrenal carcinoma. Aust. Ann. Med. 1967, 16(3):242-244.
122. Medeau V., Assie G., Zennaro M.C., Clauser E., Plouin P.F., Jeunemaitre X. Familial aspect of primary hyperaldosteronism: analysis of families compatible with primary hyperaldosteronism type 2. Ann. Endocrinol. (Paris) 2005, 66(3):240-246.
123. Miyahara K., Kawamoto T., Mitsuuchi Y., Toda K., Imura H., Gordon R.D., Shizuta Y. The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity. Biochem. Biophys. Res. Commun. 1992, 189(2):885-891.
124. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 2004, 5(9):691-701.
125. Morin E., Mete O., Wasserman J.D., Joshua A.M., Asa S.L., Ezzat S. Carney complex with adrenal cortical carcinoma. J. Clin. Endocrinol. Metab. 2012, 97(2):E202-E206.
126. Morohashi K., Honda S., Inomata Y., Handa H., Omura T. A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J. Biol. Chem. 1992, 267(25):17913-17919.
127. Moul J.W., Bishoff J.T., Theune S.M., Chang E.H. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J. Urol. 1993, 149(6):1389-1394.
128. Mulatero P., Tauber P., Zennaro M.C., Monticone S., Lang K., Beuschlein F., Fischer E., Tizzani D., Pallauf A., Viola A., Amar L., Williams T.A., Strom T.M., Graf E., Bandulik S., Penton D., Plouin P.F., Warth R., Allolio B., Jeunemaitre X., Veglio F., Reincke M. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012, 59(2):235-240.
129. Mulatero P., Monticone S., Rainey W.E., Veglio F., Williams T.A. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat. Rev. Endocrinol. 2013, 9(2):104-112.
130. Naing A., Kurzrock R., Burger A., Gupta S., Lei X., Busaidy N., Hong D., Chen H.X., Doyle L.A., Heilbrun L.K., Rohren E., Ng C., Chandhasin C., LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Can. Res. 2011, 17(18):6052-6060.
131. Naing A., Lorusso P., Fu S., Hong D., Chen H.X., Doyle L.A., Phan A.T., Habra M.A., Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br. J. Can. 2013, 108(4):826-830.
132. Nikiforova M.N., Nikiforov Y.E. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev. Mol. Diagn. 2008, 8(1):83-95.
133. Nishisho I., Nakamura Y., Miyoshi Y., Miki Y., Ando H., Horii A., Koyama K., Utsunomiya J., Baba S., Hedge P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991, 253(5020):665-669.
134. Ocker M., Sachse R., Rico A., Hensen J. PCR-SSCP analysis of human adrenocortical adenomas: absence of K-ras gene mutations. Exp. Clin. Endocrinol. Diab. 2000, 108(8):513-514.
135. Ogawa O., Eccles M.R., Szeto J., McNoe L.A., Yun K., Maw M.A., Smith P.J., Reeve A.E. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993, 362(6422):749-751.
136. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Can. Res. 2006, 66(3):1500-1508.
137. Ozata D.M., Caramuta S., Velazquez-Fernandez D., Akcakaya P., Xie H., Hoog A., Zedenius J., Backdahl M., Larsson C., Lui W.O. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrin. Relat. Cancer. 2011, 18(6):643-655.
138. Pallauf A., Schirpenbach C., Zwermann O., Fischer E., Morak M., Holinski-Feder E., Hofbauer L., Beuschlein F., Reincke M. The prevalence of familial hyperaldosteronism in apparently sporadic primary aldosteronism in Germany: a single center experience. Horm. Metab. Res. 2012, 44(3):215-220.
139. Patterson E.E., Holloway A.K., Weng J., Fojo T., Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117(8):1630-1639.
140. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell. Biol. 2010, 11(1):9-22.
141. Pilon C., Pistorello M., Moscon A., Altavilla G., Pagotto U., Boscaro M., Fallo F. Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. J. Clin. Endocrinol. Metab. 1999, 84(8):2776-2779.
142. Pinto E.M., Billerbeck A.E., Villares M.C., Domenice S., Mendonca B.B., Latronico A.C. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metab. 2004, 48(5):647-650.
143. Pratt A.J., MacRae I.J. The RNA-induced silencing complex: a versatile gene-silencing machine. J. Biol. Chem. 2009, 284(27):17897-17901.
144. Quack I., Vonend O., Rump L.C. Familial hyperaldosteronism I-III. Horm. Metab. Res. 2010, 42(6):424-428.
145. Quinkler M., Hahner S., Wortmann S., Johanssen S., Adam P., Ritter C., Strasburger C., Allolio B., Fassnacht M. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J. Clin. Endocrinol. Metab. 2008, 93(6):2057-2062.
146. Ragazzon B., Libe R., Gaujoux S., Assie G., Fratticci A., Launay P., Clauser E., Bertagna X., Tissier F., de Reynies A., Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Can. Res. 2010, 70(21):8276-8281.
147. Rainier S., Johnson L.A., Dobry C.J., Ping A.J., Grundy P.E., Feinberg A.P. Relaxation of imprinted genes in human cancer. Nature 1993, 362(6422):747-749.
148. Raymond V.M., Else T., Everett J.N., Long J.M., Gruber S.B., Hammer G.D. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2012.
149. Raymond V.M., Everett V.J.N., Furtado L.V., Gustafson S.L., Jungbluth C.R., Gruber S.B., Hammer G.D., Stoffel E.M., Greenson J.K., Giordano T.J., Else T. Adrenocortical carcinoma is a lynch syndrome-associated cancer. J. Clin. Oncol. 2013.
150. Reincke M., Beuschlein F., Latronico A.C., Arlt W., Chrousos G.P., Allolio B. Expression of adrenocorticotrophic hormone receptor mRNA in human adrenocortical neoplasms: correlation with P450scc expression. Clin. Endocrinol. (Oxf.) 1997, 46(5):619-626.
151. Reincke M., Mora P., Beuschlein F., Arlt W., Chrousos G.P., Allolio B. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 1997, 82(9):3054-3058.
152. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., Stratakis C.A., Sandrini R. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Nat. Acad. Sci. USA 2001, 98(16):9330-9335.
153. Rothenbuhler A., Stratakis C.A. Clinical and molecular genetics of Carney complex. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24(3):389-399.
154. Roy L., McDonald C.A., Jiang C., Maroni D., Zeleznik A.J., Wyatt T.A., Hou X., Davis J.S. Convergence of 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A and glycogen synthase kinase-3beta/beta-catenin signaling in corpus luteum progesterone synthesis. Endocrinology 2009, 150(11):5036-5045.
155. Roy S., Pinard S., Chouinard L., Gallo-Payet N. Adrenocorticotropin hormone (ACTH) effects on MAPK phosphorylation in human fasciculata cells and in embryonic kidney 293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R accessory protein (MRAP)beta. Mol. Cell. Endocrinol. 2011, 336(1-2):31-40.
156. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19(3):183-232.
157. Scholl U.I., Nelson-Williams C., Yue P., Grekin R., Wyatt R.J., Dillon M.J., Couch R., Hammer L.K., Harley F.L., Farhi A., Wang W.H., Lifton R.P. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc. Nat. Acad. Sci. USA 2012, 109(7):2533-2538.
158. Schussheim D.H., Skarulis M.C., Agarwal S.K., Simonds W.F., Burns A.L., Spiegel A.M., Marx S.J. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol. Metab. 2001, 12(4):173-178.
159. Seccia T.M., Mantero F., Letizia C., Kuppusamy M., Caroccia B., Barisa M., Cicala M.V., Miotto D., Rossi G.P. Somatic mutations in the KCNJ5 gene raise the lateralization index: implications for the diagnosis of primary aldosteronism by adrenal vein sampling. J. Clin. Endocrinol. Metab. 2012, 97(12):E2307-E2313.
160. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell. Biol. 2000, 10(4):147-154.
161. Sidhu S., Martin E., Gicquel C., Melki J., Clark S.J., Campbell P., Magarey C.J., Schulte K.M., Roher H.D., Delbridge L., Robinson B.G. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur. J. Surg. Oncol. 2005, 31(5):549-554.
162. Singh P.K., Buch H.N. Adrenal incidentaloma: evaluation and management. J. Clin. Pathol. 2008, 61(11):1168-1173.
163. Skogseid B., Larsson C., Lindgren P.G., Kvanta E., Rastad J., Theodorsson E., Wide L., Wilander E., Oberg K. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 1992, 75(1):76-81.
164. Skogseid B., Rastad J., Gobl A., Larsson C., Backlin K., Juhlin C., Akerstrom G., Oberg K. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 1995, 118(6):1077-1082.
165. Soon P.S., Tacon L.J., Gill A.J., Bambach C.P., Sywak M.S., Campbell P.R., Yeh M.W., Wong S.G., Clifton-Bligh R.J., Robinson B.G., Sidhu S.B. MiR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin. Can. Res. 2009, 15(24):7684-7692.
166. Stephan E.A., Chung T.H., Grant C.S., Kim S., Von Hoff D.D., Trent J.M., Demeure M.J. Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol. Can. Ther. 2008, 7(2):425-431.
167. Stowasser M., Gordon R.D. Primary aldosteronism: from genesis to genetics. Trends Endocrinol. Metab. 2003, 14(7):310-317.
168. Stratakis C.A. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr. Dev. 2008, 13:117-132.
169. Stratakis C.A. New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol. Cell. Endocrinol. 2009, 300(1-2):152-157.
170. Suzuki K., Matsubara H. Recent advances in p53 research and cancer treatment. J. Biomed. Biotechnol. 2011, 2011:978312.
171. Tadjine M., Lampron A., Ouadi L., Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin. Endocrinol. (Oxf.) 2008, 68(2):264-270.
172. Takazawa R., Ajima J., Yamauchi A., Goto M. Unusual double primary neoplasia: adrenocortical and ureteral carcinomas in werner syndrome. Urol. Int. 2004, 72(2):168-170.
173. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M., Rene-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M.C., Perret C., Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Can. Res. 2005, 65(17):7622-7627.
174. Toledo R.A., Mendonca B.B., Fragoso M.C., Soares I.C., Almeida M.Q., Moraes M.B., Lourenco D.M., Alves V.A., Bronstein M.D., Toledo S.P. Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. Clinics (Sao Paulo) 2010, 65(4):407-415.
175. Tombol Z., Szabo P.M., Molnar V., Wiener Z., Tolgyesi G., Horanyi J., Riesz P., Reismann P., Patocs A., Liko I., Gaillard R.C., Falus A., Racz K., Igaz P. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr. Relat. Can. 2009, 16(3):895-906.
176. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96(15):8681-8686.
177. Varley J.M., McGown G., Thorncroft M., James L.A., Margison G.P., Forster G., Evans D.G., Harris M., Kelsey A.M., Birch J.M. Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am. J. Hum. Genet. 1999, 65(4):995-1006.
178. Veronese A., Lupini L., Consiglio J., Visone R., Ferracin M., Fornari F., Zanesi N., Alder H., D'Elia G., Gramantieri L., Bolondi L., Lanza G., Querzoli P., Angioni A., Croce C.M., Negrini M. Oncogenic role of miR-483-3p at the IGF2/483 locus. Can. Res. 2010, 70(8):3140-3149.
179. Vincent-Dejean C., Cazabat L., Groussin L., Perlemoine K., Fumey G., Tissier F., Bertagna X., Bertherat J. Identification of a clinically homogenous subgroup of benign cortisol-secreting adrenocortical tumors characterized by alterations of the protein kinase A (PKA) subunits and high PKA activity. Eur. J. Endocrinol. 2008, 158(6):829-839.
180. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408(6810):307-310.
181. Wagner J., Portwine C., Rabin K., Leclerc J.M., Narod S.A., Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J. Natl. Can. Inst. 1994, 86(22):1707-1710.
182. Wagner A.S., Fleitz J.M., Kleinschmidt-Demasters B.K. Pediatric adrenal cortical carcinoma: brain metastases and relationship to NF-1, case reports and review of the literature. J. Neurooncol. 2005, 75(2):127-133.
183. Waldmann J., Bartsch D.K., Kann P.H., Fendrich V., Rothmund M., Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch. Surg. 2007, 392(4):437-443.
184. Waldmann J., Patsalis N., Fendrich V., Langer P., Saeger W., Chaloupka B., Ramaswamy A., Fassnacht M., Bartsch D.K., Slater E.P. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbecks Arch. Surg. 2012, 397(2):209-216.
185. Weinstein L.S., Shenker A., Gejman P.V., Merino M.J., Friedman E., Spiegel A.M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N. Engl. J. Med. 1991, 325(24):1688-1695.
186. Weksberg R., Shuman C., Beckwith J.B. Beckwith-Wiedemann syndrome. Eur. J. Hum. Genet. 2010, 18(1):8-14.
187. Wilmot Roussel H., Vezzosi D., Rizk-Rabin M., Barreau O., Ragazzon B., Rene-Corail F., de Reynies A., Bertherat J., Assie G. Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. J. Clin. Endocrinol. Metab. 2013.
188. Wortmann S., Quinkler M., Ritter C., Kroiss M., Johanssen S., Hahner S., Allolio B., Fassnacht M. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur. J. Endocrinol. 2010, 162(2):349-356.
189. Wright K.D., Gilbertson R.J. To infinium, and beyond!. Can. Cell 2010, 17(5):419-420.
190. Xiao Y.F., Yong X., Fan Y.H., Lu M.H., Yang S.M., Hu C.J. MicroRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review). Oncol. Rep. 2013, 30(2):535-544.
191. Yashiro T., Hara H., Fulton N.C., Obara T., Kaplan E.L. Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J. Surg. 1994, 18(4):455-460. (discussion 460-451).